Clinical trials: Sclerosis, Multiple
Multiple Sclerosis
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice…
- Trial name
- AVAIL (NCT01272128)
- Testing
- Interferon beta-1a
- Where
- 17 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo.
- Trial name
- NCT00086671
- Testing
- ABT-874/Human monoclonal antibody against IL-12
- Where
- 44 sites in United States, Canada and 3 more
- Volunteers
- 215 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Amyotrophic Lateral Sclerosis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
The primary objective of this study is to evaluate the safety and tolerability of BIIB078 in adults with C9ORF72-Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03626012
- Testing
- BIIB078
- Where
- 21 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- Biogen
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Multiple Sclerosis, Autoimmune Diseases
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes?
- Conditions
- Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases
- Trial name
- NCT01453764
- Testing
- Harvesting and Implantation of SVF
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Multiple Sclerosis
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
- Trial name
- START (NCT01585298)
- Testing
- FTY720
- Where
- 258 sites in Germany
- Volunteers
- 6,998 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Neuropathic Pain
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
- Trial name
- NCT01604265
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Colitis, Ulcerative
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.
- Trial name
- NCT05131971
- Testing
- GSK3888130B
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon
The study aims to investigate the relationship between sleep quality, quality of life,other disorders and therapies in Multiple Sclerosis (MS) patients treated with Betaferon.
- Trial name
- BetaSleep (NCT01766063)
- Testing
- Interferon beta-1b (Betaferon, BAY 86-5046)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Bayer
Relapsing-Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared…
- Trial name
- GLACIER (NCT01874145)
- Testing
- GA 20 mg/mL, GA 40 mg/mL
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, versus Avonex® (Biogen Idec Ltd., UK) in Patients…
- Trial name
- NCT02744222
- Testing
- BCD-054 180 mcg, Avonex®, BCD-054 240 mcg
- Where
- Russia
- Volunteers
- 399 people
- Sponsor
- Biocad
Multiple Sclerosis
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
The primary objective of the study is to determine physician reported persistence with the Avonex PEN at Month 12/End of Study as well as determining factors associated with persistence.
- Trial name
- PERSIST (NCT01405872)
- Testing
- AVONEX PEN
- Where
- 64 sites in Denmark, France and 8 more
- Volunteers
- 270 people
- Sponsor
- Biogen
Multiple Sclerosis
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults.
- Trial name
- NCT01195857
- Volunteers
- 100 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
- Trial name
- NCT06433765
- Testing
- No intervention
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- TG Therapeutics, Inc.
Neurogenic Bladder, Spinal Cord Injuries (Complete and Incomplete)
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract…
- Conditions
- Neurogenic Bladder, Spinal Cord Injuries (Complete and Incomplete), Stroke, Multiple Sclerosis
- Trial name
- CONTINENCE (NCT05301335)
- Testing
- SCONE
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 126 people
- Sponsor
- SpineX Inc.
Relapsing Multiple Sclerosis
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to…
- Trial name
- NCT07220252
- Testing
- Ublituximab, Fingolimod
- Where
- 6 sites in United States, Poland and 1 more
- Volunteers
- 240 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing-Remitting Multiple Sclerosis
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
The primary objective of the study was to measure the change in bladder function as measured by Urogenital Distress Inventory (UDI)-6 compared to baseline over 6 months of Tysabri treatment.
- Trial name
- TRUST (NCT00818038)
- Testing
- BG0002 (natalizumab)
- Volunteers
- 30 people
- Sponsor
- Biogen
Muscle Spasticity Due to Multiple Sclerosis
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
- Trial name
- NCT01649050
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Cerebral Palsy, Multiple Sclerosis
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of…
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Stroke, Neurologic Disorder
- Trial name
- EXOREG (NCT05901259)
- Testing
- EXOPULSE Mollii Suit and EXOPULSE Suit
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Multiple Sclerosis
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.
- Trial name
- NCT03209479
- Testing
- Glatiramer acetate
- Where
- Japan
- Volunteers
- 1,332 people
- Sponsor
- Teva Takeda Pharma Ltd.